Related Experiment Videos
Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions
Verena Gotta1, Stephane Bouchet2, Nicolas Widmer3
1Division of Clinical Pharmacology, Service of Biomedicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland; School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
Leukemia Research
|May 22, 2014
Summary
This study found that lower imatinib concentrations in chronic myeloid leukemia (CML) patients correlate with reduced treatment response. Early therapeutic drug monitoring (TDM) may help optimize imatinib dosage for better outcomes.
Area of Science:
- Pharmacology
- Oncology
- Hematology
Background:
- Imatinib is a crucial tyrosine kinase inhibitor for chronic myeloid leukemia (CML).
- Understanding imatinib pharmacokinetics and its correlation with treatment response is vital for patient management.
- Therapeutic drug monitoring (TDM) offers a method to assess drug concentrations in clinical practice.
Purpose of the Study:
- To analyze the relationship between imatinib trough concentrations (Cmin(400mg)) and treatment response in a large cohort of CML patients.
- To identify patient subgroups with potentially lower imatinib levels and reduced response rates.
- To evaluate the utility of early TDM for imatinib dosage optimization.
Main Methods:
- Observational study of 2478 chronic myeloid leukemia (CML) patients with centralized therapeutic drug monitoring (TDM) data.
- Estimation of individual initial trough imatinib concentrations (Cmin(400mg)) at a 400mg/day starting dose.
- Correlation analysis of Cmin(400mg) with treatment response metrics (MMR, CCyR) and adverse events using multivariate regression.
Main Results:
- Low imatinib Cmin(400mg) was predicted in young male patients and those using P-gp/CYP3A4 inducers.
- These patient subgroups exhibited lower response rates (e.g., 7% lower 18-month MMR in males, 17% lower 1-year CCyR in young patients).
- A correlation between individual Cmin(400mg) and treatment response/adverse events was confirmed, though potentially attenuated by confounding factors.
Conclusions:
- Observational data suggest a correlation between lower imatinib concentrations and reduced treatment response in CML.
- Young male patients and those on inducers may represent a subgroup benefiting from early dosage adjustments guided by TDM.
- Early TDM can assist in optimizing imatinib dosage for specific patient populations to improve therapeutic outcomes.